Sanofi and GSK start new Phase II study of COVID-19 vaccine

Sanofi and GSK start new study of COVID-19 vaccine

Sanofi and GlaxoSmithKline (GSK) have announced the initiation of a new Phase II study with 720 volunteers aged 18 and over to select the...
First real-world UK data shows high levels of protection from one dose of Pfizer/BioNTech vaccine

One dose of Pfizer/BioNTech vaccine provides high levels of protection

First real-world UK data analysed by Public Health England (PHE) has shown that the Pfizer/BioNTech vaccine provides high levels of protection against infection and...
GSK and Vir Biotechnology expand coronavirus collaboration

GSK and Vir Biotechnology expand coronavirus collaboration

GlaxoSmithKline plc (GSK) and Vir Biotechnology, Inc. have entered into an agreement to expand their existing collaboration to include the research and development of...
Why therapeutics are key to winning the COVID-19 battle

Why therapeutics are key to winning the COVID-19 battle

As the number of SARS-CoV-2 infections and deaths continues to grow, the focus of the world rests on the promise of a mass-vaccination program....
Blueprint launched for NHS reform following COVID-19 pandemic

Blueprint launched for NHS reform following COVID-19 pandemic

The Health and Social Care Secretary, with the support of NHS England and health and care system leaders, will today set out new proposals...
World’s first clinical trials of COVID-19 vaccine combination announced

World’s first clinical trials of COVID-19 vaccine combination

In a bid to combat future mutations of COVID-19, a joint research programme will begin in February 2021 to assess the immunogenicity and safety...
Oxford/AstraZeneca vaccine offers limited protection against mild disease caused by COVID-19 variant

Oxford/AstraZeneca COVID-19 vaccine offers limited protection against South African variant

Analysis submitted as a pre-print prior to peer-review publication has shown that a two-dose regimen of the Oxford/AstraZeneca COVID-19 vaccine provides minimal protection against...
One dose of Oxford/AstraZeneca COVID-19 vaccine could provide sustained

One dose of Oxford/AstraZeneca COVID-19 vaccine could provide sustained protection

Researchers at the University of Oxford have published in Preprints with The Lancet an analysis of further data from the ongoing trials of the Oxford coronavirus...
Sputnik V COVID-19 vaccine demonstrates 91.6% efficacy

Sputnik V COVID-19 vaccine demonstrates 91.6% efficacy

The Lancet has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine demonstrated efficacy of 91.6%. Sputnik V,...
EU authorisation for AstraZeneca’s COVID-19 vaccine

EU authorisation for AstraZeneca’s COVID-19 vaccine

AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 in individuals...

Latest articles

Government launches call for evidence to improve women's health and care

Government launches call for evidence to improve women’s health and care

The government is launching a 12-week call for evidence to better understand women’s experiences of the health and care system. Launching to coincide with International...
COVID-19 one year on - key changes

COVID-19 and key changes one year on

One year on from the first confirmed case of COVID-19 in the UK, Oli Hudson, Content Director at Wilmington Healthcare, takes a look at...
FDA approval for Roche’s Actemra/RoActemra in lung disease

FDA approves Roche’s Actemra/RoActemra for interstitial lung disease

Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in...

Popular articles

Image of a person descending a ladder over coronavirus to show New Normal, New Thinking: Life Post COVID-19

New Normal, New Thinking: Life Post COVID-19

New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Image of a scientist at their lab to show Study shows existing anti-parasitic drug kills coronavirus within 48 hours

Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours

A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...

Pharma marketing: UK vs US

    Marketing medicines is a totally different ball game on each side of the pond. The US is the only country, apart from New Zealand, which...
Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment

The role of women in the NHS in England

This International Women’s Day, NHS Digital has published an analysis of the role of women in the NHS in England. Women account for more than...
Nasal spray to protect against COVID-19 is ready for use in humans

Nasal spray to protect against COVID-19 is ready for use in humans

A nasal spray to provide protection against the COVID-19 virus has been formulated by researchers at the University of Birmingham, UK, using compounds already...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription